Should Everyone Be Taking Ozempic? Doctors Say More People Could Benefit1
Anti-obesity drugs are showing promise for ever-expanding list of diseases
1Loftus, P. (2025, May 25). Should Everyone Be Taking Ozempic? Doctors Say More People Could Benefit: Anti-obesity drugs are showing promise for ever-expanding list of diseases. The Wall Street Journal. https://www.wsj.com/health/pharma/glp-1-drugs-health-benefits-4014d7d5
AI article summary:2
The article discusses the increasing potential of GLP-1 drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, beyond treating diabetes and weight loss. These drugs show promise for various diseases, including heart, kidney, and liver diseases, sleep apnea, arthritis, Alzheimer’s, and alcohol addiction, and may even have anti-aging benefits.
Doctors suggest that millions more people could benefit from these drugs, potentially up to one-third to a majority of adults. However, caution is advised, as excessive weight loss and malnourishment are concerns for individuals who don’t medically fit the criteria. The drugs mimic natural gut hormones, promoting insulin production and suppressing appetite, leading to significant weight loss and improvement in related conditions.
While many benefits stem from weight loss, some may be independent, possibly due to anti-inflammatory effects. The article mentions specific examples of individuals benefiting from these drugs, like Susan Abernethy, who used Mounjaro to treat her psoriatic arthritis. There is also discussion of GLP-1s helping with liver diseases and potentially slowing cognitive decline in Alzheimer’s patients.
Despite the potential, only a small fraction of eligible people currently use these drugs, due to factors like cost, insurance coverage, tolerability, and manufacturing capacity. The article mentions ongoing research and development of newer GLP-1s with greater efficacy and different administration methods. However, certain groups, such as those with a history of thyroid cancer or pancreatitis, should avoid these drugs. Analysts predict increased usage in the future but acknowledge that it will still represent a fraction of the eligible population.
2Generated by Gemini AI